Introduction
In the development of new chemical entities for use as medicines in humans, pre-clinical screening includes investigation of the metabolism rates and routes in the safety evaluation species in order to ensure that the metabolites produced in these species are consistent with those predicted to be produced in humans. Sprague Dawley or Wistar rats are often used as the rodent species in these evaluations. CYPs are the family of hemecontaining drug-metabolizing enzymes that are involved in the biotransformation of xenobiotics, environmental contaminants, dietary components, and procarcinogens (Wrighton and Stevens, 1992; Gonzalez and Gelboin, 1994) . Rat CYP2B1/2, mouse CYP2B9/10, and human CYP2B6 share approximately 80% nucleotide sequence identity (Lewis et al., 1999) . Compared with several other CYP subfamilies, CYP2B enzymes (<1% of total CYP) exhibit a relatively low degree of catalytic preservation across mammalian species (Kedzie et al., 1991; Schenkman and Griem, 1993) . Three CYP2B isoenzymes, CYP2B1, 2B2 and 2B3, have been identified in rats (Desrochers et al., 1996) , these enzymes being the main hepatic CYP isoform inducible by phenobarbital (PB) and other barbiturates. CYP2B1 and 2B2 are structurally related isoenzymes (sharing a 97% amino acid sequence similarity; Suwa et al., 1985) with very similar substrate specificities (Waxman, 1988) . Recently, PB has been reported to induce to a significant extent mRNA expression not only of CYP2B1 (500 fold) but also of CYP3A1 (110 fold), while a much lower induction was observed with other isoforms such as CYP2C6 (4 fold), 2E1 (3 fold) and no induction of CYP2C11 mRNA expression was observed (Caron et al., 2005) . CYP2B1 is generally much more catalytically active than CYP2B2. Both are expressed constitutively in the liver and extrahepatic tissues such as small intestine and lungs (Lindell et al., 2003) . CYP2B enzymes metabolize a diverse group of compounds including pesticides (Dehal and Kupfer, 1994) , chemotherapeutics such as cyclophosphamide (Chang et al., 1993) , tobacco specific nitrosamines (Stiborova et al., 1996) , drug of abuse such as cocaine (Poet et al., 1994) , nicotine (Nakayama et al., 1993) and antidepressant (Lewis et al., 1999) including bupropion (BUP).
BUP is an aminoketone used as antidepressant and non-nicotine aid to smoking cessation (Stewart et al., 2001) . In humans, BUP is metabolized to hydroxybupropion (HBUP), the pharmacologically active main metabolite ( CYP2E1 and CYP3A4 have also been identified as participating in the metabolism of BUP, but at significantly lower rates than CYP2B6 and only at extremely high BUP concentrations (Faucette et al., 2000 (Faucette et al., , 2001 Hesse et This article has not been copyedited and formatted. The final version may differ from this version. (Suckow et al., 1986; Welch et al., 1987) but the enzyme(s) involved in this metabolic pathway has (have) to our knowledge not been identified. Previously investigated substrate probes of CYP2B1 activity include benzyloxyresorufin-Odealkylation (BROD) and pentoxyresorufin-O-dealkylation (PROD) in vitro (Burke et al., , 1994 Lubet et al., 1985) . However, it has been more recently shown that the dealkylation of benzyloxyresorufin and pentoxyresorufin are, in addition to CYP2B1, catalyzed by multiple enzymes, most notably CYP1A1/2, and to a lesser extent by CYP2C6/11/13, CYP2E1 and CYP3A1/2 (Kobayashi et al., 2002; Chovan et al., 2007) . For BROD activity, CYP2B1 showed the highest activity (0.47 pmol/min/pmol CYP), whereas CYP1A2 was also active (0.27 pmol/min/pmol CYP) (Kobayashi et al., 2002) . Therefore, alternative catalytic probes of CYP2B1 activity that are more selective would be very useful for in vitro assay. In a previous study (Richert et al., 2009), we found a poor correlation between BROD activity and CYP2B1 mRNA expression in rat hepatocytes after 24 h and 72 h of culture. By contrast, BUP hydroxylation correlated well with CYP2B1 mRNA expression at both time points. The purpose of the present study was to establish BUP hydroxylation, but not BROD, as a selective in vitro marker of CYP2B1 catalytic activity by using liver microsomes from β-naphthoflavone (BNF)-and PB-pretreated rats, in the presence and absence of known CYP inhibitors and a panel of rat cDNA-expressed CYP enzymes. This article has not been copyedited and formatted. The final version may differ from this version. 
Preparation of rat hepatocyte microsomes (RHM)
This study has been carried out in accordance with the guide for the care and use of laboratory animals.
Male Wistar rat hepatocytes were isolated as previously described by Richert et al. (2002) . Rat hepatocytes (3.5 million cells) were seeded in 60 mm dishes in Human Hepatocyte Maintenance Medium (HHMM) medium (Primacyt, Schwerin, Germany) supplemented with 5% foetal calf serum, gentamycin (50 mg/l), insulin (4 mg/l) and DEX (0.1 μ M). Cells were allowed to attach by incubating under a CO 2 /air (5%/95%) humidified atmosphere maintained at 37°C. After 4 h, the culture medium was replaced with fresh serum-free medium containing test compound. Test compounds were dissolved in serum free HHMM medium supplemented with gentamycin (50 mg/l), Insulin-Transferrin-Selenium-A Supplement, (1x, Cergy Pontoise, France) and DEX Control cultures were treated with the solvent, DMSO (0.1% v/v final concentration). The medium containing test compound was replaced every 24 h. After 24 h and 72 h of treatment, hepatocytes were harvested in homogenisation buffer and were submitted to several differential centrifugations, as previously described (Richert et al., 2002) . The final microsomal pellets were suspended in 0.25 M sucrose. All samples were stored This article has not been copyedited and formatted. The final version may differ from this version. and BUP hydroxylation (Faucette et al., 2000) .
Preparation of rat liver microsomes (RLM)
Male Wistar rats (8 weeks old) were purchased from Janvier (Saint Berthevin, France) and housed in metal cages with a 12 h light/dark cycle and were fed ad lib for 48 h. Rats were pretreated with the conventional CYP inducers, the dose and dosing periods employed were as follows: i.p. injections of BNF at 40 mg/kg in 0.8 ml corn oil for 3 days, and PB at 80 mg/kg in 0.75 ml corn oil for 3 days. The control rats received 0.8 ml corn oil vehicle only by the daily i.p. injections for the same duration. After the last treatment, rats were starved for 24 h prior to sacrifice to reduce the hepatic glycogen content. The rats were sacrificed, and the liver immediately removed and homogenized in 50 mM Tris-HCl, 150 mM KCl, 2 mM EDTA, pH 7.4. The homogenates were submitted to several differential centrifugations, as previously described (Richert et al., 2002) . Microsomal samples were frozen at −80°C until analysis. The protein content was determined using the bicinchoninic acid protein determination kit (Sigma, France) and BSA was used as a standard.
Microsomal assays
Microsomal BROD was determined according to Burke et al. (1985) . Briefly, RLM (0.04 mg protein) were incubated for 2 min at 37° C with benzyloxyresorufin (20.5 μM) in Tris buffer as substrate in a total volume of 0.1 ml. The reaction was initiated by adding NADPH (1 mM) and was stopped with ZnSO 4 (87 mM) and Ba(OH) 2 (79 mM). Following centrifugation (800 g, 5 min) to remove precipitated protein, the fluorescent metabolite resorufin was measured by spectrofluorometry (excitation 530 nm and emission 580 nm). Calibration standards (1.25 -50 pmol/ml) were prepared by adding known amounts of resorufin to microsomes and incubation buffer. Results were expressed as pmol resorufin formed/min/mg microsomal proteins. Rates of HBUP formation were determined using insect cell-derived microsomes and RLMs according to Faucette et al. (2000) . Preliminary experiments in RLMs and insect cell-derived microsomes were conducted to identify 8 62.5 mM potassium phosphate buffer (pH 7.4), 1 mM EDTA, 3 mM magnesium chloride, 1 mM NADPH in a total volume of 0.25 ml. All BUP stock solutions were prepared in methanol. Reactions in RLMs were initiated at 37°C by the addition of NADPH and stopped after 30 min with 125 µl of ice-cold acetonitrile. Incubation mixtures were centrifuged at 3000 rpm for 5 min. The supernatant (100 µl) was injected onto the HPLC column.
Similar procedures were followed for incubations with microsomes containing cDNA-expressed CYP enzymes, except that reactions were initiated by adding ice-cold microsomes rather than NADPH and then analyzed by LC/MS/MS.
HPLC Analysis.
The HPLC system for detection of HBUP consisted of an Agilent 1100 liquid chromatography (Agilent Technologies, Waldbronn, Germany) connected to a Agilent Technologies model 1100 UV detector set at 210 nm. Peak of interest was separated on a 5 µm BDS Hypersil 15x0.46 cm C18 column (Thermo Scientific, France). Mobile phases A (0.1% triethylamine) and B (100% acetonitrile) were pumped at a flow rate of 1 ml/min using a gradient ranging from 10 to 20 % B at 0 to 7.5 min, 20 to 50% B at 7.5 to 8 min, 50% B at 8 to 12.5 min and 10% B at 12.5 to 13 min. The column temperature was maintained at 35°C. HBUP peaks were integrated using an Agilent ChemStation system. Retention time for HBUP was approximately 8.7 min.
Calibration standards (120 -2400 pmol/ml) were prepared by adding known amounts of HBUP to microsomes and reagent stock. HBUP concentrations were calculated from the peak area using least-squares linear regression, with weighting by the reciprocal of the squared standard concentrations. Interday coefficients of variation for calibration standards ranged from 12.5% for the lowest standard to 5% for the highest standard. The lower limit of detection was 120 pmol/ml. This concentration is lower than HBUP concentrations observed in rat plasma up to 4 h after 40 mg/kg i.p. dose of BUP (Suckow et al., 1986) .
LC/MS/MS Analysis.
The mass spectrophotometer used was Varian (Les Ulis, France) 320 MS triple quadrupole with pump 
Statistical Analyses
BROD activities in RHM were compared to BUP hydroxylase activities in the same microsomal samples using the linear regression program of GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA). p values for the r-squared (r 2 ) were determined from an F test. The acceptance limit for statistical significance was set at α = 0.05.
Inhibition of BROD and BUP Hydroxylase Activities by Selective Inhibitors.
The effects of ANF (CYP1A2 inhibitor), metyrapone (CYP2B1 inhibitor), proadifen (CYP1A2/2B1 inhibitor) on BROD and BUP hydroxylase activities were evaluated in BNF-pretreated and PB-pretreated RLMs.
The inhibition experiments were conducted with 0.001 to 100 µM of inhibitors at 500 µM BUP for BUP hydroxylation or 20.5 µM benzyloxyresorufin for BROD. This pilot experiment was performed to confirm the ability of metyrapone and proadifen to inhibit the BROD and BUP hydroxylation by using both PB-pretreated RLM and cDNA-expressed CYP2B1. The indicated amounts of inhibitor were pre-incubated on ice with 0.05 mg RLMs for 5 min before reactions were initiated by addition of reagent stock consisting of 500 µM BUP in 62.5 mM potassium phosphate buffer (pH 7.4) or 20.5 µM benzyloxyresorufin in Tris buffer, and 1mM NADPH. 
Results

Correlation between BUP hydroxylase and BROD activities in RHM
Correlations between BUP hydroxylase and BROD activities were examined in RHMs isolated from various rat hepatocyte cultures, controls (n=5) or treated with CYP2B1 inducer (PB, n=3), CYP3A1 inducer (DEX, n=5), CYP4A inducer (FEN, n=4) or CYP1A2 inducers (3-MC or BNF, n=5) (Fig. 2) . The substrates were used in excess, i.e. at a concentration of 500 µM BUP and 20.5 µM benzyloxyresorufin. When including 3-MC and BNF-treated groups, BUP hydroxylase activity did not correlate well with BROD activity (r 2 = 0.49, p = 0.014, Fig. 2 Fig. 2; ). This suggests that BROD was not selective for CYP2B1 activity, since neither 3-MC nor BNF would be expected to induce CYP2B1.
Inhibition Experiments
The pilot experiment was performed to confirm the ability of proadifen and metyrapone to inhibit the BUP hydroxylation and BROD by using cDNA-expressed CYP2B1. Proadifen and metyrapone effectively inhibited cDNA-expressed CYP2B1-dependent BUP hydroxylase activity with an IC 50 of 14.9 ± 3.7 and 7.52 ± 0.54 µM, respectively (Table 1) . These two inhibitors also effectively inhibited cDNA-expressed CYP2B1-dependent BROD activity with an IC 50 of 38.1 ± 1.3 and 1.85 ± 1.11 µM, respectively (Table 1) . To determine the potential substrate selectivity of BUP for CYP2B1 but not CYP1A2 involved in these reactions, liver microsomes from BNF-and PB-pretreated rats were used. BROD activity and BUP hydroxylation were measured in these microsomes pre-incubated or not with three known CYP inhibitors in the presence of substrate prior to the addition of NADPH which initiates enzyme activity (Table 1) . When incubated with PB-induced RLM, proadifen (CYP1A2/2B1 inhibitor) and metyrapone (CYP2B1 inhibitor) caused a great reduction in both BROD and BUP hydroxylation, the IC 50 being 1.21 ± 0.49 and 3.89 ± 1.54 µM for BUP hydroxylation and 0.688 ± 0.161 and 0.806 ± 0.663 µM for BROD, respectively as seen in Table1. By contrast, in BNF-induced RLM, the IC 50s for BROD by ANF (CYP1A2 inhibitor) and proadifen was much lower (2.5x10 -3 ± 0.8x10 -3 µM)
than that of BUP hydroxylation (>100 µM), while the IC 50s for BROD activity and BUP hydroxylation were equivalent (40.8 ± 4.6 and 41.8 ± 3.4 µM, respectively) in the presence of metyrapone (CYP2B1 inhibitor).
This article has not been copyedited and formatted. The final version may differ from this version. Taken all together, these results suggest that CYP2B1 is similarly involved in both activities, whereas CYP1A1/2 is involved in BROD activity, but not in BUP hydroxylation.
Evaluation of BUP Hydroxylation by Individual cDNA-expressed Rat CYPs.
A panel of fourteen cDNA-expressed enzymes (SUPERSOMES) was screened for BUP hydroxylase activity at 500 and 2500 µM BUP (Fig. 3) . These substrate concentrations were selected to ensure saturation of any high K m isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B1 exhibited the highest percentage of total BUP hydroxylation at 2500 µM BUP (75%), as compared to 63% at 500 µM BUP. Two other cDNA-expressed CYPs also contributed to BUP hydroxylation but to a lower rates: CYP2C11 participated for 23% and 8.7% of total HBUP, at 500 and 2500 µM BUP respectively, and CYP2E1 participated for 1.8 and 10.9% of total HBUP, respectively at 500 and 2500 µM BUP. Rates of BUP hydroxylation by CYP1A1, CYP1A2, CYP2A1, CYP2A2, CYP2C6, CYP2C12, CYP2C13, CYP2D1, CYP2D2, CYP3A1 and CYP3A2
were less than 10% of total HBUP formation. HBUP formation in control microsomes was undetectable.
Kinetic Analyses of BUP Hydroxylation
Kinetic parameters of BUP hydroxylation were first estimated by fitting kinetic data with PB-pretreated RLM ( Fig. 4A ) and by fitting kinetic data with cDNA-expressed CYP2B1 (Fig. 4B) to the single enzyme Michaelis-Menten equation. The apparent K m and V max for BUP hydroxylation in the PB-pretreated RLM with single enzyme kinetics were 158.5 ± 23.1 µM and 1697 ± 81 pmol/min/mg protein, respectively (Table 2 ) and the apparent K m and V max for BUP hydroxylation by cDNA-expressed CYP2B1 were 152.5 ± 11.5 µM and 181.2 ±5.5 pmol/min/pmol CYP, respectively (Table 2 ). Kinetic parameters of BUP hydroxylation were also estimated by fitting kinetic data with cDNA-expressed CYP 2E1, 2C6, 2C11 and 3A1. The apparent K m and V max for BUP hydroxylation by cDNA-expressed CYP2E1 were 914 ± 305 µM and 0.143 ± 0.020 pmol/min/pmol CYP, respectively (Fig. 5A ). Substrate inhibition for BUP hydroxylation was observed with cDNA-expressed CYP2C6 (Fig. 5B) , 2C11 (Fig. 5C ) and 3A1 (Fig. 5D) for BUP concentrations over 500 µM. Using the substrate inhibition model (Lin et al.,2001) , the K m for BUP hydroxylation by cDNA-expressed CYP2C6, 2C11 and 3A1
were 67.8 ± 11.8, 190 ± 52.5 and 453 ± 81.7 µM, respectively. V max for BUP hydroxylation by cDNA-expressed CYP2C6, 2C11 and 3A1 were 0.219 ± 0.016, 1.65 ± 0.30 and 0.376 ± 0.044 pmol/min/pmol CYP, i.e. more than 100 times lower than that of cDNA-expressed CYP2B1.
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Discussion
Over the past several decades, CYP2B enzymes have served as prototypical models for investigation of the mechanism by which drugs and environmental contaminants activate gene expression. CYP2B enzymes are also very versatile catalysts with a broad range of substrates including drugs, environmental pollutants, and steroids (Kedzie et al., 1991) . CYP2B is the main hepatic CYP isoform inducible by PB and other barbiturates in experimental animals, CYP2B-mediated biotransformations being extensively studied in both small rodents and in rabbit (Nims and Lubets, 1996) . In humans, BUP hydroxylation has been shown to be a selective marker of CYP2B6 (Faucette et al., 2000) but to our knowledge, a fully selective probe for CYP2B1 catalytic activity in rodent, that would facilitate further examination of the role of this enzyme in xenobiotic metabolism, has not been described. Indeed although BROD is routinely used for evaluating CYP2B1 activity (Burke et al., , 1994 Lubet et al., 1985) , it can also be partly related to CYP1A2 activity (Kobayashi et al., 2002; Chovan et al., 2007) . In a previous study (Richert et al., 2009 ), we found a good correlation between BUP hydroxylation and CYP2B1 mRNA expression in rat hepatocyte cultures. The results of the present study support the use of BUP at saturating concentrations as a selective in vitro probe substrate for the determination of CYP2B1 catalytic activity.
Previous reports described that BROD reaction clearly involved multiple enzymes: according to Kobayashi et al. (2002) , CYP2B1 accounted for 60% and CYP1A2 for 35% and according to Chovan et al. (2007) the respective involvements of CYP2B1 and CYP1A2 were 32% and 34%. In the present study, the apparent K m for BUP hydroxylation in PB-pretreated RLM (158.5 ± 23.1 µM) was equivalent to that of cDNAexpressed CYP2B1 (152.5 ± 11.5 µM). Although this observation alone cannot support the conclusion that a single enzyme is involved in BUP hydroxylation in RLM, these results are in accordance with data obtained with human CYP2B6 for which it has been reported that BUP is metabolized primarily by CYP2B6 to HBUP with an apparent K m of 107.5 ± 20.5 µM (Ekins et al., 1999) or of 155.8 ± 18.2 µM (Faucette et al., 2000) in human cDNA-expressed CYP2B6 and an apparent K m of 130.2 ± 22.0 µM. in human liver microsomes (Faucette et al., 2000) .
The results from inhibition experiments by using IC 50 values as a measure of the efficacy of inhibition of microsomal CYP1A2 and CYP2B1 activities, further suggest the selectivity of CYP2B1 for BUP hydroxylation but not BROD. Proadifen and metyrapone effectively inhibited cDNA-expressed CYP2B1-dependent BUP hydroxylase activity with an IC 50 of 14.9 ± 3.7 and 7.52 ± 0.54 µM, respectively. IC 50 for BROD and BUP hydroxylation were equivalent (40.8 ± 4.6 and 41.8 ± 3.4 µM, respectively) when using liver This article has not been copyedited and formatted. The final version may differ from this version. 14 microsomes from BNF-pretreated rats in the presence of metyrapone, a CYP2B1-selective inhibitor. However, when using liver microsomes from rats pretreated with BNF, in the presence of ANF a CYP1A1/2-selective inhibitor, we found an IC 50 of 2.5x10 -3 ± 0.8x10 -3 µM for BROD while >100 µM for BUP hydroxylation. These results suggest that CYP2B1 is similarly involved in both activities, whereas CYP1A1/2 is involved in BROD activity, but not in BUP hydroxylation. This is further supported by the good correlation of BUP hydroxylation with BROD activity (r 2 = 0.81, p < 0.01; Fig. 2 ) when considering control, DEX-, FEN-and PB-treated rat hepatocytes cultures but poor correlation when including rat hepatocytes treated with CYP1A2 inducer (3-MC and BNF) (r 2 = 0.49, p = 0.014). In CYP1A2 induced rat hepatocytes, BROD activity was increased while BUP hydroxylase activity was unchanged, clearly demonstrating that BROD is not selective for CYP2B1 activity, since neither 3-MC nor BNF would be expected to induce CYP2B1. Our data confirm the principle role of CYP2B1 in catalyzing HBUP formation, as suggested by our finding of a good correlation between CYP2B1 expression and BUP hydroxylation but not BROD activity (Richert et al., 2009) .
Since the early 1990s, the use of cDNA-expressed CYPs has assisted, in addition to liver microsomes, in the evaluation of metabolic specificity of probe substrates and the identification of the CYP enzymes involved in the metabolism of xenobiotics in human and rat liver microsomes. We show that, among a panel of fourteen rat cDNA-expressed CYP isozymes (CYP1A1, CYP1A2, CYP2A1, CYP2A2, CYP2B1, CYP2C6, CYP2C11, CYP2C12, CYP2C13, CYP2D1, CYP2D2, CYP2E1, CYP3A1 and CYP3A2), the rate of BUP hydroxylation at high concentrations of BUP (500 µM and 2500 µM) was highest with CYP2B1. When using BUP at 2500 µM to ensure saturation of any high K m isozyme capable of catalyzing BUP hydroxylation, two other CYP isozymes,
i.e. CYP2C11 and CYP2E1, were also found to be catalytically competent (8.7% and 10.9% of total HBUP formation respectively, as compared to 75% for CYP2B1). Previous in vitro studies dealing with the involvement of human CYP using various BUP concentrations reached similar conclusions (Chen et al., 2010) ; also Faucette et al. (2000 Faucette et al. ( , 2001 and Hesse et al. (2000) both reported that although CYP2B6 was the major isoform (71%) involved in BUP hydroxylation, CYP2E1 and CYP3A4 can also be involved in BUP hydroxylation (respectively 24% and 2%). 15 (190 ± 52.5 µM), were close to that of CYP2B1 (152.5 ± 11.5 µM) and suggest that at low concentrations of BUP, the CYP2C isoforms can be involved in BUP metabolism. As plasmatic concentrations of BUP in rat have been shown to be 4 µM (Suckow et al., 1986) , BUP cannot be used in vivo as a marker for CYP2B1 activity.
However, the apparent V max for CYP2C isoforms were very low (0.22 ± 0.02 pmol/min/pmol CYP for CYP2C6 and 1.65 ± 0.30 pmol/min/pmol CYP for CYP2C11) compared to V max for BUP hydroxylation with cDNAexpressed CYP2B1 (181.2 ± 5.5 pmol/min/pmol CYP). In addition, substrate inhibition of the CYP2C isoforms occurs from BUP concentrations over 500 µM, while no such effect was found with CYP2B1. As a consequence, the involvement of the CYP2C isoforms in BUP hydroxylation at saturating concentrations of BUP are negligible compared to CYP2B1.
Taken all together, the data suggest that BUP is a selective probe substrate for CYP2B1, characterized by a relatively high K m value (158.5 µM) that maintains CYP selectivity due to the absence of other significantly contributing CYP isozymes, especially at saturating BUP concentrations. Other selective substrates have high K m value such as the caffeine for human CYP1A2 (K m ~ 1.2 mM) (Hickman et al., 1998) , tolbutamide for human CYP2C9 (K m ~ 200 µM) (Hickman et al., 1998) and testosterone for rat CYP3A1 (K m ~ 150 µM) (Cooper et al., 1993 ).
In conclusion, this study validates BUP hydroxylation as an in vitro diagnostic marker for CYP2B1 catalytic activity when assayed at >500 μM BUP. This will now allow the assessment of the contribution of CYP2B1 to the metabolism of the given drug.
